-
WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference
•
China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where its chief executive officer (CEO) Chen Zhisheng outlined the company’s strategic direction and achievements. Despite negative global macroeconomic conditions and inclusion on the US unverified list, WuXi Biologics has maintained its business model and continued…
-
Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its generic version of cyclophosphamide, marketed as Endoxan by UK firm Hikma Pharmaceuticals USA Inc. The approval allows Hengrui to market its capsules for the treatment of a wide range of…
-
ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion
•
Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of Germany-listed Co.Don AG (FRA: CNW), gaining rights to its cartilage repair cell therapy Spherox/Chondrosphere. The move comes as the Hong Kong-based company secured over USD 36 million in a Series A financing round led by…
-
Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication
•
China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its PD-1 inhibitor penpulimab (AK105). The drug is now approved for the treatment of first-line or locally advanced/metastatic squamous non-small cell lung cancer (sqNSCLC) in combination with chemotherapy. This marks a…
-
Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in China, with a strategic focus on 2023. The company expects to begin the commercial launch of SCB-2019 in multiple provinces and municipalities in China during the first…
-
JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline
•
Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million) in a Series A+ financing round. The funding was led by 3E Bioventures and Guangdian Capital. Proceeds from the round will be allocated towards the development and expansion of JHM Biopharma’s product pipeline, as well…
-
Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing for the combination of its anti-PD-L1 monoclonal antibody (mAb) TQB2450 and anlotinib has been accepted for review by the Center for Drug Evaluation (CDE). The Phase III study for this combination in first-line small cell…
-
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
•
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered into a partnership with UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) to handle the import and distribution of Evusheld (tixagevimab, cilgavimab) in mainland China. Evusheld is a COVID-19 prophylactic neutralizing antibody combination designed to provide…
-
Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038
•
Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and controlled release drug OPL-038. The drug, filed as an Investigational New Drug (IND) under Category 2 (modified drug), aims to address the needs of adult patients with type 2 diabetes through a novel combination therapy.…
-
Eyougene Raises Hundreds of Millions in Series B Funding for Expansion
•
Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The funding was led by Hangzhou Point Investment Management, with a contribution from Lingdu Capital. The proceeds will be used for research…
-
LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion
•
Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF…
-
Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion
•
Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has reportedly raised over RMB 100 million (USD 14.86 million) in a Series C financing round. The funding was led by Kinghall Ventures, with contributions from Hawkins Capital and Plow Capital. The proceeds will be used…
-
Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
•
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study of its innovative Alzheimer’s disease (AD) drug, OAB-14. The study will assess the safety and tolerability, pharmacokinetics, pharmacodynamics, and food effects of OAB-14 in…
-
Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry
•
China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The funding was solely led by a fund from Oak Acorn Capital. The proceeds will be allocated towards the research and development of…
-
TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline
•
TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by Chengdu Biological City No. 1 Equity Investment Fund Partnership and Chengdu High-tech New Economy Venture Capital. The proceeds will be used…
-
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
•
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study of its Category 1 chemical drug KC1036. The study will assess the efficacy and safety of KC1036 in combination with docetaxel for the treatment of…
-
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
•
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States, and China, has announced receiving approval from the US Food and Drug Administration (FDA) to conduct an open-label, multi-center Phase I study of its monoclonal antibody (mAb) HBM1020. The study will assess the safety, tolerability,…
-
Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a bio-industry park in Slovenia, marking a significant expansion of its presence in the European market. The project will involve an investment of EUR 50 million (USD 54.2 million) and will include the construction of an…
-
ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced a strategic partnership with compatriot firms Shaanxi Pharmaceutical Holding Group Co., Ltd and Shaanxi Pharmaceutical Holding Pai Ang. The collaboration aims to leverage the respective resources and expertise of the three companies to enhance drug…
